We are live on ! Find out more
ALBO

Albireo Pharma Inc
ALBO

Delisted

ALBO was delisted on the 2nd of March, 2023.

Back to rankings

67 hedge funds and large institutions have $256M invested in Albireo Pharma Inc in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 26 increasing their positions, 18 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 18

3% less funds holding

Funds holding: 69 → 67 (-2)

5% less capital invested

Capital invested by funds: $270M → $256M (-$13.7M)

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

Holders
67
Holders Change
-2
Holders Change %
-2.9%
% of All Funds
1.53%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
26
Reduced
18
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PM
Prosight Management
Texas
+$5.33M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$2.27M
3
BlackRock
BlackRock
New York
+$1.96M
4
ACH
ArrowMark Colorado Holdings
Colorado
+$1.4M
5
MWNA
Marshall Wace North America
New York
+$1.12M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.8M
2
Renaissance Technologies
Renaissance Technologies
New York
-$2.13M
3
Millennium Management
Millennium Management
New York
-$1.24M
4
Two Sigma Investments
Two Sigma Investments
New York
-$1.08M
5
EMG
Ellington Management Group
Connecticut
-$444K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$56.2M – – –
TGHSA
2
TPG Group Holdings (SBS) Advisors
Texas
$23.6M – – –
Federated Hermes
3
Federated Hermes
Pennsylvania
$19.3M +$2K +61 +0%
BlackRock
4
BlackRock
New York
$19.3M +$1.96M +59,901 +11%
ACH
5
ArrowMark Colorado Holdings
Colorado
$18.3M +$1.4M +42,818 +8%
AG
6
Artal Group
Luxembourg
$16.5M – – –
Fidelity Investments
7
Fidelity Investments
Massachusetts
$15.9M -$4.8M -146,732 -23%
BBA
8
Baker Bros. Advisors
New York
$8.24M – – –
BI
9
BVF Inc
California
$7.21M -$39.2K -1,200 -0.5%
SAM
10
Sectoral Asset Management
Quebec, Canada
$6.25M +$549K +16,775 +10%
PM
11
Prosight Management
Texas
$5.37M +$5.33M +162,905 New
CC
12
Chicago Capital
Illinois
$5.28M +$834K +25,500 +19%
State Street
13
State Street
Massachusetts
$4.82M +$192K +5,868 +4%
Vanguard Group
14
Vanguard Group
Pennsylvania
$4.19M +$36.3K +1,109 +0.9%
HA
15
Heartland Advisors
Wisconsin
$4.12M – – –
TCM
16
Tekla Capital Management
Massachusetts
$4.12M – – –
DM
17
Deerfield Management
New York
$3.96M – – –
Northern Trust
18
Northern Trust
Illinois
$3.75M +$455K +13,900 +14%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$2.88M +$203K +6,216 +8%
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$2.73M +$2.27M +69,431 +518%
Millennium Management
21
Millennium Management
New York
$2.18M -$1.24M -37,981 -37%
WMSA
22
Weiss Multi-Strategy Advisers
New York
$1.81M -$2.19K -67 -0.1%
Victory Capital Management
23
Victory Capital Management
Texas
$1.7M -$92.2K -2,820 -5%
Renaissance Technologies
24
Renaissance Technologies
New York
$1.39M -$2.13M -65,234 -61%
Allianz Asset Management
25
Allianz Asset Management
Germany
$1.27M +$107K +3,275 +9%
1
2 3

ALBO Hedge Fund Activity: Q3 2018 in Review

67 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q3 2018, worth a combined $256M — down 5.1% from $270M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ALBO and 5 opened new positions — a net loss of 2 holders — while 18 trimmed existing stakes and 26 added.

The largest buyer was Prosight Management, opening a new position worth an estimated $5.33M. The largest seller was Fidelity Investments, cutting an estimated $4.8M.

  • 67 institutional investors held Albireo Pharma Inc (ALBO) as of Q3 2018, down from 69 in Q2 2018.
  • Funds reported $256M of Albireo Pharma Inc stock for Q3 2018, down 5.1% quarter-over-quarter.
  • 5 funds opened new Albireo Pharma Inc positions in Q3 2018 and 7 closed out, a net change of -2 holders.
  • The largest Albireo Pharma Inc buyer in Q3 2018 was Prosight Management, an estimated $5.33M added.
  • The largest Albireo Pharma Inc seller in Q3 2018 was Fidelity Investments, an estimated $4.8M sold.

Based on aggregated 13F filings for Q3 2018.